Needham & Company LLC reaffirmed their hold rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report published on Tuesday morning, AnalystRatings.com reports.
A number of other brokerages also recently issued reports on RGLS. Wedbush reissued a hold rating and issued a $1.00 price target on shares of Regulus Therapeutics in a report on Thursday, May 16th. Zacks Investment Research downgraded shares of Regulus Therapeutics from a buy rating to a hold rating in a report on Wednesday, July 10th. Finally, ValuEngine raised shares of Regulus Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Regulus Therapeutics presently has an average rating of Hold and an average target price of $1.08.
Shares of Regulus Therapeutics stock opened at $0.56 on Tuesday. Regulus Therapeutics has a 12-month low of $0.50 and a 12-month high of $4.08. The company has a market cap of $11.87 million, a price-to-earnings ratio of -0.10 and a beta of 1.90. The company’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.08.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 32.8% in the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,751 shares in the last quarter. Virtu Financial LLC purchased a new stake in Regulus Therapeutics in the first quarter valued at approximately $68,000. CVI Holdings LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at approximately $568,000. Samsara BioCapital LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at approximately $1,131,000. Finally, EcoR1 Capital LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at approximately $1,389,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Recommended Story: What is a CD ladder?
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.